Abstract
Ovarian carcinoma is the leading cause of gynecological cancer-related mortality. Cytoreductive surgery followed by combination chemotherapy including paclitaxel and a platinum compound usually results in complete remission in approximately 70% of patients. Despite this, the majority of patients will eventually relapse and die. There is, therefore, a crucial need to develop new therapeutic agents and better strategies to improve the outcome of these patients. Recently, tumor microenvironment has become an attractive target in gynecological malignancies. Angiogenesis is a complex and highly regulated process consisting in the development of new vessels from pre-existing ones. This process has been shown to have a main role in cancer beginning and progression. In ovarian cancer increased angiogenesis is associated with rapid recurrence and decreased survival. Moreover, targeting of vascular endothelial growth factor (VEGF) has produced promising results in early clinical trials, suggesting that angiogenesis plays a critical role in the development and maintenance of ovarian carcinomas. However, many questions remain open related to optimal dosing, sequencing of therapies, toxicities, patient selection, and response assessment. This article reviews the mechanisms of the angiogenic process and resumes the latest clinical studies of antivascular agents in ovarian carcinoma in a “from bench to bedside” approach.
Keywords: Ovary, cancer, angiogenesis, VEGF, Bevacizumab, targeted therapy
Current Cancer Therapy Reviews
Title: Targeting Angiogenesis in Ovarian Carcinoma
Volume: 5 Issue: 3
Author(s): Marta Mendiola, Jorge Barriuso and David Hardisson
Affiliation:
Keywords: Ovary, cancer, angiogenesis, VEGF, Bevacizumab, targeted therapy
Abstract: Ovarian carcinoma is the leading cause of gynecological cancer-related mortality. Cytoreductive surgery followed by combination chemotherapy including paclitaxel and a platinum compound usually results in complete remission in approximately 70% of patients. Despite this, the majority of patients will eventually relapse and die. There is, therefore, a crucial need to develop new therapeutic agents and better strategies to improve the outcome of these patients. Recently, tumor microenvironment has become an attractive target in gynecological malignancies. Angiogenesis is a complex and highly regulated process consisting in the development of new vessels from pre-existing ones. This process has been shown to have a main role in cancer beginning and progression. In ovarian cancer increased angiogenesis is associated with rapid recurrence and decreased survival. Moreover, targeting of vascular endothelial growth factor (VEGF) has produced promising results in early clinical trials, suggesting that angiogenesis plays a critical role in the development and maintenance of ovarian carcinomas. However, many questions remain open related to optimal dosing, sequencing of therapies, toxicities, patient selection, and response assessment. This article reviews the mechanisms of the angiogenic process and resumes the latest clinical studies of antivascular agents in ovarian carcinoma in a “from bench to bedside” approach.
Export Options
About this article
Cite this article as:
Mendiola Marta, Barriuso Jorge and Hardisson David, Targeting Angiogenesis in Ovarian Carcinoma, Current Cancer Therapy Reviews 2009; 5 (3) . https://dx.doi.org/10.2174/157339409788982223
DOI https://dx.doi.org/10.2174/157339409788982223 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Implication of CYP24A1 Splicing in Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Three-Dimensional Ultrasound in Gynecology: Current Status and Future Perspectives
Current Women`s Health Reviews Clomiphene Citrate, Metformin or Both for Ovulation Induction in Therapy Naïve Women with Polycystic Ovary Syndrome (PCOS)? A Descriptive Review
Current Drug Therapy Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance
Current Neuropharmacology Design of Lipophilic Prodrugs to Improve Drug Delivery and Efficacy
Current Drug Targets Targeting Inhibitor of Apoptosis Proteins (IAPs) for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Antidiabetic Drugs: Mechanisms of Action and Potential Outcomes on Cellular Metabolism
Current Pharmaceutical Design Poly (ADP-Ribosyl) Polymerase 1 Inhibitors: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery Review of the Third Domain Receptor Binding Fragment of Alphafetoprotein (AFP): Plausible Binding of AFP to Lysophospholipid Receptor Targets
Current Drug Targets Preliminary Analysis of Anti-proliferative, Apoptotic, and Anti-migratory Effects llw-3-6 in Skov-3 Ovarian Cystadenocarcinoma Cell Line
Letters in Drug Design & Discovery Cranberry as Promising Natural Source of Potential Anticancer Agents: Current Evidence and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry Functional Nanogels for Biomedical Applications
Current Medicinal Chemistry Chemopreventive Properties of Indole-3-Carbinol, Diindolylmethane and Other Constituents of Cardamom Against Carcinogenesis
Recent Patents on Food, Nutrition & Agriculture CXCR4 Inhibitors: Tumor Vasculature and Therapeutic Challenges
Recent Patents on Anti-Cancer Drug Discovery Recent Advances in Multinuclear Complexes as Potential Anticancer and DNA Binding Agents
Anti-Cancer Agents in Medicinal Chemistry Targeting Blood Vessels for the Treatment of Non-Small Cell Lung Cancer
Current Cancer Drug Targets The Non-Canonical IκB Kinases IKKε and TBK1 as Potential Targets for the Development of Novel Therapeutic Drugs
Current Molecular Medicine From 2D to 3D - a New Dimension for Modelling the Effect of Natural Products on Human Tissue
Current Pharmaceutical Design Perspectives of Protein Kinase C (PKC) Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry Mechanisms of Resistance Against Cancer Therapeutic Drugs
Current Pharmaceutical Biotechnology